{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,13]],"date-time":"2026-09-13T04:47:58Z","timestamp":1789274878335,"version":"build-2803163510"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"},{"start":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T00:00:00Z","timestamp":1610150400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Headache Pain"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec>\n                <jats:title>Background<\/jats:title>\n                <jats:p>The CGRP antagonists offer a novel therapeutic approach in migraine. Their utility in patients with severe forms of chronic migraine is a subject of particular interest. We present outcomes of 9\u2009months of erenumab treatment in a cohort of patients with difficult-to-control chronic migraine, all of whom had prior unsatisfactory response to onabotulinumtoxinA.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Methods<\/jats:title>\n                <jats:p>We offered erenumab to 98 patients with a prior unsatisfactory response to onabotulinumtoxinA. Eighty of 98 had trialled greater occipital nerve injections (82%), 32\/98 peripheral neurostimulation (33%) and 18\/98 intravenous dihydroergotamine (18%). Thirty eight of 98 (39%) met the definition of triptan overuse and 43\/98 (44%) analgesic overuse. All patients met the EHF criteria for \u2018resistant migraine\u2019. Outcome measures (recorded monthly) included days with headache limiting activities of daily living (\u201cred\u201d), not limiting (\u201camber\u201d), headache free (\u201cgreen\u201d), and requiring triptans or other analgesics. Quality of life scores - headache impact test 6 (HIT-6), patient health questionnaire 9 (PHQ-9) and pain disability index (PDI) - were also measured.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Results<\/jats:title>\n                <jats:p>Mean number of red days improved by \u2212\u20096.4\u2009days (SE 0.67, 95%CI \u2212\u20097.7 to \u2212\u20095.1, <jats:italic>p<\/jats:italic>=0.001) at 3 months; \u2212\u20096.8\u2009days (SE 0.96, 95%CI \u2212\u20098.80 to \u2212\u20094.9, <jats:italic>p<\/jats:italic>=0.001) at 6 months and \u2212\u20096.5\u2009days (SE 0.86, 95%CI \u2212\u20098.3 to \u2212\u20094.8, <jats:italic>p<\/jats:italic>=0.001) at 9 months. Repeated measures ANOVA confirmed improvements in the number of red (<jats:italic>p<\/jats:italic>=0.001), green (<jats:italic>p<\/jats:italic>=0.001), triptan (<jats:italic>p<\/jats:italic>=0.001) and painkiller days (<jats:italic>p<\/jats:italic>=0.001) as well as scores of the HIT-6 (<jats:italic>p<\/jats:italic>=0.001), PHQ-9 (<jats:italic>p<\/jats:italic>=0.001), and PDI (<jats:italic>p<\/jats:italic>=0.001) across the duration of study.<\/jats:p>\n              <\/jats:sec><jats:sec>\n                <jats:title>Conclusion<\/jats:title>\n                <jats:p>We observed improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment.<\/jats:p>\n              <\/jats:sec>","DOI":"10.1186\/s10194-020-01214-2","type":"journal-article","created":{"date-parts":[[2021,1,9]],"date-time":"2021-01-09T17:03:18Z","timestamp":1610211798000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":43,"title":["Improvements in pain, medication use and quality of life in onabotulinumtoxinA-resistant chronic migraine patients following erenumab treatment \u2013 real world outcomes"],"prefix":"10.1186","volume":"22","author":[{"given":"J.","family":"Talbot","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Stuckey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Crawford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Weatherby","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Mullin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,1,9]]},"reference":[{"issue":"3","key":"1214_CR1","doi-asserted-by":"publisher","first-page":"445","DOI":"10.1177\/0333102418821662","volume":"39","author":"DW Dodick","year":"2019","unstructured":"Dodick DW (2019) CGRP ligand and receptor monoclonal antibodies for migraine prevention: evidence review and clinical implications. Cephalalgia Int J Headache 39(3):445\u2013458","journal-title":"Cephalalgia Int J Headache"},{"issue":"6","key":"1214_CR2","doi-asserted-by":"publisher","first-page":"1026","DOI":"10.1177\/0333102418759786","volume":"38","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Ashina M, Brandes JL, Kudrow D, Lanteri-Minet M, Osipova V et al (2018) ARISE: a phase 3 randomized trial of erenumab for episodic migraine. Cephalalgia 38(6):1026\u20131037","journal-title":"Cephalalgia"},{"issue":"19","key":"1214_CR3","doi-asserted-by":"publisher","first-page":"1999","DOI":"10.1001\/jama.2018.4853","volume":"319","author":"DW Dodick","year":"2018","unstructured":"Dodick DW, Silberstein SD, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2018) Effect of fremanezumab compared with placebo for prevention of episodic migraine: a randomized clinical trial. JAMA 319(19):1999\u20132008","journal-title":"JAMA"},{"issue":"12","key":"1214_CR4","doi-asserted-by":"publisher","first-page":"1237","DOI":"10.1212\/WNL.0000000000004391","volume":"89","author":"M Ashina","year":"2017","unstructured":"Ashina M, Dodick D, Goadsby PJ, Reuter U, Silberstein S, Zhang F et al (2017) Erenumab (AMG 334) in episodic migraine: interim analysis of an ongoing open-label study. Neurology 89(12):1237\u20131243","journal-title":"Neurology"},{"issue":"9","key":"1214_CR5","doi-asserted-by":"publisher","first-page":"1080","DOI":"10.1001\/jamaneurol.2018.1212","volume":"75","author":"VL Stauffer","year":"2018","unstructured":"Stauffer VL, Dodick DW, Zhang Q, Carter JN, Ailani J, Conley RR (2018) Evaluation of galcanezumab for the prevention of episodic migraine: the EVOLVE-1 randomized clinical trial. JAMA Neurol 75(9):1080\u20131088","journal-title":"JAMA Neurol"},{"issue":"22","key":"1214_CR6","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa1709038","volume":"377","author":"SD Silberstein","year":"2017","unstructured":"Silberstein SD, Dodick DW, Bigal ME, Yeung PP, Goadsby PJ, Blankenbiller T et al (2017) Fremanezumab for the preventive treatment of chronic migraine. N Engl J Med 377(22):2113\u20132122","journal-title":"N Engl J Med"},{"issue":"24","key":"1214_CR7","doi-asserted-by":"publisher","first-page":"e2211","DOI":"10.1212\/WNL.0000000000006640","volume":"91","author":"HC Detke","year":"2018","unstructured":"Detke HC, Goadsby PJ, Wang S, Friedman DI, Selzler KJ, Aurora SK (2018) Galcanezumab in chronic migraine: the randomized, double-blind, placebo-controlled REGAIN study. Neurology 91(24):e2211\u2013e2221","journal-title":"Neurology"},{"issue":"6","key":"1214_CR8","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1016\/S1474-4422(17)30083-2","volume":"16","author":"S Tepper","year":"2017","unstructured":"Tepper S, Ashina M, Reuter U, Brandes JL, Dole\u017eil D, Silberstein S et al (2017) Safety and efficacy of erenumab for preventive treatment of chronic migraine: a randomised, double-blind, placebo-controlled phase 2 trial. Lancet Neurol 16(6):425\u2013434","journal-title":"Lancet Neurol"},{"issue":"11","key":"1214_CR9","doi-asserted-by":"publisher","first-page":"1091","DOI":"10.1016\/S1474-4422(15)00245-8","volume":"14","author":"ME Bigal","year":"2015","unstructured":"Bigal ME, Edvinsson L, Rapoport AM, Lipton RB, Spierings EL, Diener H-C et al (2015) Safety, tolerability, and efficacy of TEV-48125 for preventive treatment of chronic migraine: a multicentre, randomised, double-blind, placebo-controlled, phase 2b study. Lancet Neurol 14(11):1091\u20131100","journal-title":"Lancet Neurol"},{"issue":"1","key":"1214_CR10","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1212\/WNL.0000000000002801","volume":"87","author":"ME Bigal","year":"2016","unstructured":"Bigal ME, Dodick DW, Krymchantowski AV, VanderPluym JH, Tepper SJ, Aycardi E et al (2016) TEV-48125 for the preventive treatment of chronic migraine: efficacy at early time points. Neurology 87(1):41\u201348","journal-title":"Neurology"},{"issue":"1","key":"1214_CR11","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1071-3","volume":"21","author":"O Raffaele","year":"2020","unstructured":"Raffaele O, Alfonsina C, Ilaria F, Amleto G, Giannapia A, Adele GM et al (2020) Real-life data on the efficacy and safety of erenumab in the Abruzzo region, central Italy. J Headache Pain 21(1):1","journal-title":"J Headache Pain"},{"issue":"1","key":"1214_CR12","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1071-3","volume":"21","author":"L Giorgio","year":"2020","unstructured":"Giorgio L, Hill B, Murphy M, Ivona T, Andreou AP (2020) A prospective real-world analysis of erenumab in refractory chronic migraine. J Headache Pain 21(1):1","journal-title":"J Headache Pain"},{"key":"1214_CR13","doi-asserted-by":"publisher","first-page":"417","DOI":"10.3389\/fneur.2020.00417","volume":"11","author":"B Raffaelli","year":"2020","unstructured":"Raffaelli B, Kalantzis R, Mecklenburg J, Overeem LH, Neeb L, Gendolla A et al (2020) Erenumab in chronic migraine patients who previously failed five first-line Oral prophylactics and OnabotulinumtoxinA: a dual-center retrospective observational study. Front Neurol 11:417","journal-title":"Front Neurol"},{"issue":"10","key":"1214_CR14","doi-asserted-by":"publisher","first-page":"2555","DOI":"10.1111\/head.13968","volume":"60","author":"S Cheng","year":"2020","unstructured":"Cheng S, Jenkins B, Limberg N, Hutton E (2020) Erenumab in chronic migraine: an Australian experience. Headache J Head Face Pain 60(10):2555\u20132562","journal-title":"Headache J Head Face Pain"},{"issue":"9","key":"1214_CR15","doi-asserted-by":"publisher","first-page":"2014","DOI":"10.1111\/head.13951","volume":"60","author":"J Robblee","year":"2020","unstructured":"Robblee J, Devick KL, Mendez N, Potter J, Slonaker J, Starling AJ (2020) Real-world patient experience with Erenumab for the preventive treatment of migraine. Headache J Head Face Pain 60(9):2014\u20132025","journal-title":"Headache J Head Face Pain"},{"key":"1214_CR16","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-020-04667-0","volume":"41","author":"E Matteo","year":"2020","unstructured":"Matteo E, Favoni V, Pascazio A, Pensato U, Benini M, Asioli GM et al (2020) Erenumab in 159 high frequency and chronic migraine patients: real-life results from the Bologna headache center. Neurol Sci 41:1\u20132","journal-title":"Neurol Sci"},{"key":"1214_CR17","first-page":"1","volume":"41","author":"FS di Cola","year":"2020","unstructured":"di Cola FS, Rao R, Caratozzolo S, Di Cesare M, Venturelli E, Balducci U et al (2020) Erenumab efficacy in chronic migraine and medication overuse: a real-life multicentric Italian observational study. Neurol Sci 41:1\u20132","journal-title":"Neurol Sci"},{"key":"1214_CR18","first-page":"1","volume":"41","author":"U Pensato","year":"2020","unstructured":"Pensato U, Favoni V, Pascazio A, Benini M, Asioli GM, Merli E et al (2020) Erenumab efficacy in highly resistant chronic migraine: a real-life study. Neurol Sci 41:1\u20133","journal-title":"Neurol Sci"},{"key":"1214_CR19","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-020-04665-2","volume":"41","author":"C Disco","year":"2020","unstructured":"Disco C, Billo G, De Boni A, De Luca C, Perini F (2020) Efficacy of erenumab 70 mg in chronic migraine: Vicenza experience. Neurol Sci 41:1\u20132","journal-title":"Neurol Sci"},{"key":"1214_CR20","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/s10072-020-04677-y","volume":"41","author":"A Ranieri","year":"2020","unstructured":"Ranieri A, Alfieri G, Napolitano M, Servillo G, Candelaresi P, Di Iorio W et al (2020) One year experience with erenumab: real-life data in 30 consecutive patients. Neurol Sci 41:1\u20132","journal-title":"Neurol Sci"},{"key":"1214_CR21","doi-asserted-by":"publisher","first-page":"1511","DOI":"10.1177\/0333102420946725","volume":"40","author":"S Kanaan","year":"2020","unstructured":"Kanaan S, Hettie G, Loder E, Burch R (2020) Real-world effectiveness and tolerability of erenumab: a retrospective cohort study. Cephalalgia 40:1511\u20131522","journal-title":"Cephalalgia"},{"key":"1214_CR22","volume-title":"Erenumab in highly therapy-refractory migraine patients: first real-world evidence","author":"D Holle-Lee","year":"2020","unstructured":"Holle-Lee D, Scheffler A, Messel O, Wurthmann S, Nsaka M, Kleinschnitz C, et al. Erenumab in highly therapy-refractory migraine patients: first real-world evidence. 2020"},{"issue":"1","key":"1214_CR23","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-020-01143-0","volume":"21","author":"A Russo","year":"2020","unstructured":"Russo A, Silvestro M, di Clemente FS, Trojsi F, Bisecco A, Bonavita S et al (2020) Multidimensional assessment of the effects of erenumab in chronic migraine patients with previous unsuccessful preventive treatments: a comprehensive real-world experience. J Headache Pain 21(1):1\u201314","journal-title":"J Headache Pain"},{"issue":"3","key":"1214_CR24","doi-asserted-by":"publisher","first-page":"E191","DOI":"10.1503\/cmaj.110829","volume":"184","author":"L Manea","year":"2012","unstructured":"Manea L, Gilbody S, McMillan D (2012) Optimal cut-off score for diagnosing depression with the patient health questionnaire (PHQ-9): a meta-analysis. CMAJ 184(3):E191\u2013E196","journal-title":"CMAJ"},{"issue":"3","key":"1214_CR25","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1177\/0333102410379890","volume":"31","author":"M Yang","year":"2011","unstructured":"Yang M, Rendas-Baum R, Varon SF, Kosinski M (2011) Validation of the headache impact test (HIT-6\u2122) across episodic and chronic migraine. Cephalalgia 31(3):357\u2013367","journal-title":"Cephalalgia"},{"issue":"4","key":"1214_CR26","doi-asserted-by":"publisher","first-page":"158","DOI":"10.3988\/jcn.2008.4.4.158","volume":"4","author":"HE Shin","year":"2008","unstructured":"Shin HE, Park JW, Kim YI, Lee KS (2008) Headache impact Test-6 (HIT-6) scores for migraine patients: their relation to disability as measured from a headache diary. J Clin Neurol 4(4):158\u2013163","journal-title":"J Clin Neurol"},{"issue":"2","key":"1214_CR27","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/0304-3959(90)90068-O","volume":"40","author":"RC Tait","year":"1990","unstructured":"Tait RC, Chibnall JT, Krause S (1990) The pain disability index: psychometric properties. Pain 40(2):171\u2013182","journal-title":"Pain"},{"issue":"1","key":"1214_CR28","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1071-3","volume":"21","author":"S Simona","year":"2020","unstructured":"Simona S, Braschinsky M, Ducros A, Lampl C, Little P, Pozo-Rosich P et al (2020) European headache federation consensus on the definition of resistant and refractory migraine. J Headache Pain 21(1):1\u20132","journal-title":"J Headache Pain"},{"issue":"12","key":"1214_CR29","doi-asserted-by":"publisher","first-page":"1194","DOI":"10.1097\/00005650-200412000-00006","volume":"42","author":"B L\u00f6we","year":"2004","unstructured":"L\u00f6we B, Un\u00fctzer J, Callahan CM, Perkins AJ, Kroenke K (2004) Monitoring depression treatment outcomes with the patient health questionnaire-9. Med Care 42(12):1194\u20131201","journal-title":"Med Care"},{"issue":"1","key":"1214_CR30","doi-asserted-by":"publisher","first-page":"29","DOI":"10.1177\/0333102413497599","volume":"34","author":"AF Smelt","year":"2014","unstructured":"Smelt AF, Assendelft WJ, Terwee CB, Ferrari MD, Blom JW (2014) What is a clinically relevant change on the HIT-6 questionnaire? An estimation in a primary-care population of migraine patients. Cephalalgia 34(1):29\u201336","journal-title":"Cephalalgia"},{"issue":"8","key":"1214_CR31","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1097\/BRS.0b013e31822c8a7a","volume":"37","author":"R Soer","year":"2012","unstructured":"Soer R, Reneman MF, Vroomen PC, Stegeman P, Coppes MH (2012) Responsiveness and minimal clinically important change of the pain disability index in patients with chronic back pain. Spine 37(8):711\u2013715","journal-title":"Spine"},{"issue":"1","key":"1214_CR32","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s10194-019-1054-4","volume":"20","author":"R Ornello","year":"2019","unstructured":"Ornello R, Tiseo C, Frattale I, Perrotta G, Marini C, Pistoia F et al (2019) The appropriate dosing of erenumab for migraine prevention after multiple preventive treatment failures: a critical appraisal. J Headache Pain 20(1):1\u20136","journal-title":"J Headache Pain"}],"container-title":["The Journal of Headache and Pain"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01214-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/article\/10.1186\/s10194-020-01214-2\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1186\/s10194-020-01214-2.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,1,12]],"date-time":"2021-01-12T21:08:09Z","timestamp":1610485689000},"score":1,"resource":{"primary":{"URL":"https:\/\/thejournalofheadacheandpain.biomedcentral.com\/articles\/10.1186\/s10194-020-01214-2"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,1,9]]},"references-count":32,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["1214"],"URL":"https:\/\/doi.org\/10.1186\/s10194-020-01214-2","relation":{},"ISSN":["1129-2369","1129-2377"],"issn-type":[{"value":"1129-2369","type":"print"},{"value":"1129-2377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,1,9]]},"assertion":[{"value":"9 October 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"26 December 2020","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 January 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"This study was registered locally as an audit, which under current national guidelines does not require research ethics committee review (). Participants all signed a consent form, as stipulated in the methods.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"SW has attended conferences\/ received speakers fees from Novartis.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"5"}}